460 related articles for article (PubMed ID: 28752560)
1. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
Maura G; Pariente A; Alla F; Billionnet C
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
4. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
[TBL] [Abstract][Full Text] [Related]
9. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA
BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
Charlton A; Vidal X; Sabaté M; Bailarín E; Martínez LML; Ibáñez L
J Manag Care Spec Pharm; 2021 Sep; 27(9):1210-1220. PubMed ID: 34464214
[No Abstract] [Full Text] [Related]
12. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
14. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
Mueller T; Alvarez-Madrazo S; Robertson C; Bennie M
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1378-1386. PubMed ID: 28752670
[TBL] [Abstract][Full Text] [Related]
15. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
Mentias A; Shantha G; Chaudhury P; Vaughan Sarrazin MS
JAMA Netw Open; 2018 Sep; 1(5):e182870. PubMed ID: 30646182
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
18. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
[TBL] [Abstract][Full Text] [Related]
19. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Pham PN; Brown JD
BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
[TBL] [Abstract][Full Text] [Related]
20. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1027-1036. PubMed ID: 33822401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]